Kyntra Bio Inc

Kyntra Bio’s recent insider sale and option block reveal balanced liquidity needs while hinting at upside once FDA milestones are hit, offering investors a nuanced view of its early‑stage biotech outlook.

Insightful look at Kyntra Bio’s recent insider sales amid a shaky stock price and pending clinical data, revealing what executives’ moves mean for investors.